within Pharmacolibrary.Drugs.ATC.B;

model B06AA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 20 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1500 / 1000000,
    adminCount     = 1,
    Vd             = 0.0045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Hyaluronidase is an enzyme that depolymerizes hyaluronic acid, a constituent of the extracellular matrix. It is used to enhance the absorption and dispersion of other injected drugs, improve resorption of radiopaque agents in subcutaneous urography, and in the management of extravasation as well as ophthalmic surgery to facilitate tissue penetration. Hyaluronidase is approved and in clinical use today.</p><h4>Pharmacokinetics</h4><p>No published peer-reviewed pharmacokinetic models are available for hyaluronidase in humans. Available data suggest very rapid inactivation following subcutaneous administration, believed to be mainly via tissue and plasma proteases. These estimates are based on indirect and non-quantitative data.</p><h4>References</h4><ol><li><p>Burotto, M, et al., &amp; Felip, E (2023). IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications. <i>Annals of oncology : official journal of the European Society for Medical Oncology</i> 34(8) 693–702. DOI:<a href=&quot;https://doi.org/10.1016/j.annonc.2023.05.009&quot;>10.1016/j.annonc.2023.05.009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37268157/&quot;>https://pubmed.ncbi.nlm.nih.gov/37268157</a></p></li><li><p>Liu, L (2018). Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. <i>Protein &amp; cell</i> 9(1) 15–32. DOI:<a href=&quot;https://doi.org/10.1007/s13238-017-0408-4&quot;>10.1007/s13238-017-0408-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28421387/&quot;>https://pubmed.ncbi.nlm.nih.gov/28421387</a></p></li><li><p>Frost, GI (2007). Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. <i>Expert opinion on drug delivery</i> 4(4) 427–440. DOI:<a href=&quot;https://doi.org/10.1517/17425247.4.4.427&quot;>10.1517/17425247.4.4.427</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17683255/&quot;>https://pubmed.ncbi.nlm.nih.gov/17683255</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B06AA03;
